All Drug Development articles – Page 11
-
WhitepaperAccurate and Reproducible Quantitation of xC/UV/MS Data from Any Instrument
Learn how Medtronic processes and quantifies their xC/UV/MS data using the quantitation workflow in MS Workbook Suite.
-
ReportPharma Horizons: Artificial Intelligence
EPR’s latest Pharma Horizons report explores the latest advances in artificial intelligence (AI) for drug and clinical development, regulation and more.
-
NewsFDA approves first-in-class oral antibiotic
The drug is the first in a new class of oral antibiotics for uncomplicated urinary tract infections in nearly three decades.
-
WebinarLeveraging early insights to accelerate the oral drug development cycle
This webinar explores oral drug product development and how to address critical challenges such as complex formulations and regulatory hurdles.
-
NewsMSD to advance investigational Lp(a) inhibitor in nearly $2b deal
The new license agreement will support development of a potential additional treatment option for patients at risk of atherosclerosis.
-
NewsDrug for rare form of Alzheimer’s “scientifically promising”
The anti-amyloid drug study highlights the importance of longer-term follow-up to determine benefits and risks of dementia treatments.
-
NewsAstraZeneca cell therapy acquisition to advance in vivo therapies
The company’s new acquisition, valued up to $1 billion, supports development of in vivo cancer treatments and the future of cell therapy.
-
NewsNanomaterial research potential “game-changer” for drug delivery
The throughput achieved by the researchers exceeded that of other reported methods by orders of magnitude, supporting the advancement of precision nanomaterials.
-
NewsEuropean Commission approves Rytelo for LR- MDS-related anaemia
The European marketing authorisation offers a new treatment option for patients with transfusion-dependent anaemia in lower-risk myelodysplastic syndromes (LR-MDS), who are unresponsive to erythropoiesis-stimulating agents.
-
WhitepaperImproving Method Transfer Outcomes
A collaboration with Pfizer to create a tool to ensuring seamless method transfer between labs.
-
NewsNICE recommends innovative endometriosis pill
Approximately 1,000 eligible NHS patients could benefit from the new endometriosis treatment annually.
-
NewsBristol Myers Squibb to acquire 2seventy bio
The proposed acquisition, worth nearly $300 million, could help to advance cell therapy in the oncology field.
-
NewsInvestigational plaque psoriasis treatments show promise in late-stage trials
With the Phase III trials demonstrating sustained skin clearance in plaque psoriasis, this could lead to patients accessing more treatment options to manage the autoimmune inflammatory disease.
-
WebinarSafety reporting in clinical trials: six core considerations for success
This webinar will provide guidance in navigating the terrain of pharmacovigilance, including regulatory challenges, and gain a deeper understanding of the pivotal role played by safety reporting in clinical research.
-
NewsCHMP meeting highlights – February 2025
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of four new medicines plus the extension of therapeutic indications for 16 medicines.
-
Whitepaper
Deepening Digitalization in Drug Discovery at PTC Therapeutics
PTC Therapeutics accelerates drug discovery process by integrating physicochemical property predictions into their Dotmatics ELN.
-
ArticlePreparing for a new era in the rare disease sector
To mark Rare Disease Day 2025, EPR interviewed Christina Gkousgkouni, Head of Rare Diseases for Central South Europe, Sanofi.
-
NewsImaging discovery could accelerate drug development
The organic fluorophore’s super-photostability enables tracking of previously undetectable biological processes hindered with traditional fluorescent dyes.
-
NewsCould novel 3D printing method enhance intestinal drug delivery?
The research suggests that the innovative 3D printing method has “great” potential for personalised treatments of intestinal inflammatory diseases.
-
NewsNICE recommends novel immunotherapy for leukaemia
The agency’s decision means eligible adult patients in the UK are set to access the combination immunotherapy as a new treatment option for acute lymphoblastic leukaemia (ALL).